A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 1139-1143

  Bai, Chenguang ^a   Liu, Xiaohong ^a   Zheng, Jian Ming ^a   Qiu, Cen ^a   Zhu, Yan ^a   Xu, Jingjing ^a   Zhao, Jing ^a   Ma, Dalie ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug sensitivity; Gastrointestinal stromal tumour; Imatinib; PDGFRA mutant

Indexed keywords

COMPLEMENTARY DNA; IMATINIB; LIPOSOME; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CANCER INHIBITION; CHO CELL; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84863275745     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.599     Document Type: Article

References (29)

1. Miettinen M and Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466-1478, 2006.
2. Meng L, Fang SH and Jin M: An unusual case of pancreatic and gastric neoplasms (2010: 12b). Malignant GISTs originating from the pancreas and stomach. Eur Radiol 21: 663-665, 2011.
3. Huizinga JD, Thuneberg L, Klüppel M, Malysz J, Mikkelsen HB and Bernstein A: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347-349, 1995.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A and Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11: 728-734, 1998.
5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465, 2002.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
7. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121, 2001.
8. Corless CL, Fletcher JA and Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825, 2004.
9. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125: 660-667, 2003.
10. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003.
11. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
12. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423, 2001.
13. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA and Pilotti S: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-299, 2004.
14. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2002.
15. Waller CF: Imatinib mesylate. Recent Results Cancer Res 184: 3-20, 2010.
16. Cassier PA and Blay JY: Imatinib mesylate for the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 10: 623-634, 2010.
17. Lopes LF and Bacchi CE: Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med 14: 42-50, 2010.
18. Marin D: Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol 47: 312-318, 2010.
19. Mauro MJ and Druker BJ: STI571: targeting BCR-ABL as therapy for CML. Oncologist 6: 233-238, 2001.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, et al: Imatinib mesylate in chordoma. Cancer 101: 2086-2097, 2004.
21. Kérob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, et al: Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 16: 3288-3295, 2010.
22. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.
23. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J and Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357-5364, 2005.
24. Yang L, Bai CG, Hou XW, Liu XH and Ma DL: Transforming effect of PDGFRA gene mutant on the cell function in gastrointestinal stromal tumor. Zhonghua Zhong Liu Za Zhi 31: 500-504, 2009 (In Chinese).
25. Lasota J and Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53: 245-266, 2008.
26. Lasota J and Miettinen M: KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23: 91-102, 2006.
27. Frost MJ, Ferrao PT, Hughes TP and Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1: 1115-1124, 2002.
28. Merkelbach-Bruse S, Dietmaier W, Füzesi L, Gaumann A, Haller F, Kitz J, Krohn A, Mechtersheimer G, Penzel R, Schildhaus HU, et al: Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med Genet 11: 106, 2010.
29. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H and von Mehren M: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27: 3141-3147, 2009.